Health Condition 1: K812- Acute cholecystitis with chronic cholecystitis
Conditions
Interventions
None listed
Sponsors
Cliniexperts Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subject in group of 18-65 years(age of ascent) 2. Written and/or witnessed informed consent to participate in the trial was taken prior to initiating the study from parent and/or legally accepted representative 3.Patients who had at least six months previous history of confirmed diagnosis of colic
Exclusion criteria
Exclusion criteria: 1. Not willing to sign ICF 2. Patients Known or thought to be hypersensitivity, to study drug 3. Pregnant and lactating women 4. patient with history of hypersensitivity to Camylofin or Diclofenac Sodium 5. Patient with prostatic hypertrophy 6. Patients with glaucoma 7. Patient with mechanical stenosis 8. Patients with serious underlying organic disorders 9. Patients with paralytic ileus 10. Patient with renal and hepatic disorder 11. Patient with previous history of heart problems and stroke. 12. Participation in another clinical trial in last months and doing study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary StudyObjective The primary objective of this trial is to evaluate safety & tolerability of the FDC in treatment ofColic Secondary Study Objective Thesecondaryobjectiveofthis trialis toevaluateefficacyofthis FDCintreatmentofColic. Timepoint: 1 hour 3 hours and 24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Study Objective The secondary objective of this trial is to evaluate efficacy of thisTimepoint: 1 hour 3 hours and 24 hours | — |
Countries
India
Contacts
Public ContactDr Devesh Kumar
IR Innovate research Private Limited
Outcome results
None listed